Global Blood Therapeutics Inc. (NASDAQ:GBT) went down by -0.91% during the previous trading session, and it is maintaining the win ahead of Thursday’s trading session. The share price of the Biotechnology giant went up by $64.16 to trade ended Thursday trading at $64.75. This is down from the $64.75 price recorded on Wednesday’s trading session. Thanks to this latest performance, GBT is closer to the higher price 52-week target of $150.00 and further from the lowest price target of $60.00. Its performance from the start of the year has also been negative, with GBT down by -19.29% year-to-date.
Global Blood Therapeutics Inc. (GBT) started the day trading at $64.1 and recorded an intraday high of $64.31. It also recorded an intraday low of $62.745 during Thursday’s trading session. Global Blood Therapeutics Inc. is a very active stock that recorded a trading volume that is less than -83.93% of the average daily trading volume on Thursday. The stock’s trading volume on Thursday was 485444, which is less than -83.93 of the total average daily trading volume of 892.86K.
Global Blood Therapeutics Inc. (NASDAQ:GBT) 2020 Performance Impressive
The increase in GBT’s stock price on Thursday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of GBT currently stands at $87.54, which is higher than the current trading price of the stock by 26.71%. However, GBT’s current trading price is -60.6% lower than the 52-week low price of $39.95. In terms of trading volume, Global Blood Therapeutics Inc. currently experienced healthy participation during the last trading session. 485444 shares of Global Blood Therapeutics Inc. were traded on the stock exchange on Thursday, which is less than -83.93% of the 892.86K average trading volume of the stock.
The performance of the stock has been positive over the past year. GBT’s performance over the past one year has seen it surge by 9.58%, while the stock has gone down by -17.51% in the last six months. The quarterly performance of GBT currently stands at 40.21%, and it is down by -8.04% in the last month. The only positive figure was from the weekly performance, which currently reads 2.57%. At the time of writing GBT’s report, the company has a total market cap of $3.90B, making it one of the largest publicly-traded companies in the world.Global Blood Therapeutics Inc. also has over 352 employees all over the world.
GBT Insider Activities
The insider transactions over the past six months are up by 5.20%.For Global Blood Therapeutics Inc. insiders bought 184,872 shares in 31 transactions. In that same period, insiders sold 278,047 of their shares in 44 transactions. After these transactions, insiders at Global Blood Therapeutics Inc. now hold 1.51M shares, which is over 101.84% of the total company stocks. Institutional investors currently hold a large chunk of the GBT shares, as they control 2.48% of the company’s total stock.
GBT Fundamental Analysis
For Global Blood Therapeutics Inc., the stock’s diluted earnings per share (EPS) stands at -4.88. In the coming year, analysts expect the EPS to be -2.63. The EPS growth will up over the next five years to 37.00% after plunging by -33.20% in the previous five years. In terms of revenue, Global Blood Therapeutics Inc.’s quarterly sales (YOY) is shrinking at -1.17, which is higher than the average annual revenue of -33.20% over the past half a decade.
The Return on Investment (ROI) on Global Blood Therapeutics Inc.’s stock currently stands at -43.10%. The gross margin of the company is 98.90%.
GBT Analysts Prediction
The SunTrust has a Hold rating for Global Blood Therapeutics Inc., predicting the stock price to stay between $110 and $75. Another analyst that has a Overweight rating for GBT is Cantor Fitzgerald, which set a price target of between $110 and $98.
Analysts at H.C. Wainwright believe that GBT is Buy, and they have a price target of between $125 and $150. H.C. Wainwright and H.C. Wainwright also believe that Global Blood Therapeutics Inc.’s stock is outperforming at the moment. Three analysts, Piper Jaffray, Cantor Fitzgerald, and Cantor Fitzgerald, all rate the stock as overweight.
At the moment, Global Blood Therapeutics Inc.’s Total Debt to Equity ratio stands at 0.14, and they have a long-term Debt to Equity ratio of 0.14.
GBT Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of GBT currently stands at -4.14%, while the SMA50 is -8.89%. The biggest one is the SMA200, which is currently reading 0.89% ahead of Thursday’s trading session. The Relative Strength Index of this stock is 43.04.